Randomized Phase II study of the Addition of Targeted Therapeutic Agents to Tafasitamab-based Therapy in Non-Transplant-Eligible Patients With Relapsed/Refractory Large B-cell Lymphoma

Sponsor:

SWOG

Sponsor Study ID:

S2207

CTO #:

104146

NCT Number:

NCT05890352

Phase:

II

Protocol Type:

Treatment

Age Group:

Adults

Disease Sites:

Non-Hodgkin's Lymphoma

Study Objectives:

To determine the recommended phase II dose of tafasitamab + lenalidomide + tazemetostat AND of tafasitamab + lenalidomide + zanubrutinib.

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)

---

Request more information